Abiopharma

🔍 DUFFIELD DAVID A (Executive)

Company: Workday, Inc. (WDAY)

Report Date: 2026-03-31

Detailed Transactions and Holdings:

• Acquired 107,500 shares of Class A Common Stock (Direct)
  Date: 2026-03-31 | Code: C | equity_swap_involved: 0 | shares_owned_after: 212,549.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,800 shares of Class A Common Stock at $128.0853 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 208,749.00 | transaction_form_type: 4 | Footnotes: F2, F3, F1
• Sold 16,932 shares of Class A Common Stock at $129.0503 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 191,817.00 | transaction_form_type: 4 | Footnotes: F2, F4, F1
• Sold 72,781 shares of Class A Common Stock at $129.8375 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 119,036.00 | transaction_form_type: 4 | Footnotes: F2, F5, F1
• Sold 13,887 shares of Class A Common Stock at $130.6666 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 105,149.00 | transaction_form_type: 4 | Footnotes: F2, F6, F1
• Sold 100 shares of Class A Common Stock at $131.41 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 105,049.00 | transaction_form_type: 4 | Footnotes: F2, F7, F1
• Sold 107,500 shares of Class B Common Stock (Derivative)
  Date: 2026-03-31 | Code: C | equity_swap_involved: 0 | shares_owned_after: 37,743,834.00 | transaction_form_type: 4 | Footnotes: F8, F8, F8, F1

Footnotes:

• F1: The reported shares are held by the David A. Duffield Trust dated July 14, 1988, a revocable living trust, of which the Reporting Person is trustee and sole beneficiary.
• F2: This sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the David A. Duffield Trust dated December 2, 2025.
• F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $127.38 to $128.3799, inclusive. The Reporting Person undertakes to provide to Workday, Inc., any security holder of Workday, Inc., or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
• F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $128.38 to $129.3799, inclusive. The Reporting Person undertakes to provide to Workday, Inc., any security holder of Workday, Inc., or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
• F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $129.38 to $130.3799, inclusive. The Reporting Person undertakes to provide to Workday, Inc., any security holder of Workday, Inc., or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
• F6: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $130.38 to $131.3799, inclusive. The Reporting Person undertakes to provide to Workday, Inc., any security holder of Workday, Inc., or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
• F7: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $131.41 to $132.4099, inclusive. The Reporting Person undertakes to provide to Workday, Inc., any security holder of Workday, Inc., or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
• F8: All shares of Class A and Class B Common Stock will convert automatically into shares of a single class of Common Stock upon the earliest to occur of the following: (a) upon the election by the holders of a majority of the then outstanding shares of Class B Common Stock, (b) the date when the number of outstanding shares of Class B Common Stock represents less than 9% of all outstanding shares of Class A and Class B Common Stock, (c) October 11, 2032 or (d) nine months after the death of the later to die of David A. Duffield and Aneel Bhusri. The shares of Class A and Class B Common Stock have no expiration date.
• F9: Each share of Class B Common Stock is convertible, at any time at the option of the holder, into one (1) share of Class A Common Stock. In addition, each share of Class B Common Stock will convert automatically into one (1) share of Class A Common Stock upon any transfer, whether or not for value, except for certain permitted transfers described in, and transfers to any "permitted transferee" as defined in, the Issuer's restated certificate of incorporation in effect as of the date hereof. The shares of Class B Common Stock have no expiration date.